Non-Invasive Epigenetic Detection of Fetal Trisomy 21 in First Trimester Maternal Plasma by Lim, Ji Hyae et al.
Non-Invasive Epigenetic Detection of Fetal Trisomy 21 in
First Trimester Maternal Plasma
Ji Hyae Lim
1, Shin Young Kim
1, So Yeon Park
1, Shin Yeong Lee
1, Mi Jin Kim
1, You Jung Han
2, Si Won
Lee
2, Jin Hoon Chung
2, Moon Young Kim
2, Jae Hyug Yang
2, Hyun Mee Ryu
1,2*
1Laboratory of Medical Genetics, Medical Research Institute, Cheil General Hospital and Women’s Healthcare Center, Seoul, Korea, 2Department of Obstetrics and
Gynecology, Cheil General Hospital and Women’s Healthcare Center, KwanDong University college of Medicine, Seoul, Korea
Abstract
Background: Down syndrome (DS) is the most common known aneuploidy, caused by an extra copy of all or part of
chromosome 21. Fetal-specific epigenetic markers have been investigated for non-invasive prenatal detection of fetal DS.
The phosphodiesterases gene, PDE9A, located on chromosome 21q22.3, is completely methylated in blood (M-PDE9A) and
unmethylated in the placenta (U-PDE9A). Therefore, we estimated the accuracy of non-invasive fetal DS detection during the
first trimester of pregnancy using this tissue-specific epigenetic characteristic of PDE9A.
Methodology/Principal Findings: A nested, case-control study was conducted using maternal plasma samples collected
from 108 pregnant women carrying 18 DS and 90 normal fetuses (each case was matched with 5 controls according to
gestational weeks at blood sampling). All pregnancies were singletons at or before 12 weeks of gestation between October
2008 and May 2009. The maternal plasma levels of M-PDE9A and U-PDE9A were measured by quantitative methylation-
specific polymerase chain reaction. M-PDE9A and U-PDE9A levels were obtained in all samples and did not differ between
male and female fetuses. M-PDE9A levels did not differ between the DS cases and controls (1854.3 vs 2004.5 copies/mL;
P=0.928). U-PDE9A levels were significantly elevated in women with DS fetuses compared with controls (356.8 vs
194.7 copies/mL, P,0.001). The sensitivities of U-PDE9A level and the unmethylation index of PDE9A for non-invasive fetal
DS detection were 77.8% and 83.3%, respectively, with a 5% false-positive rate. In the risk assessment for fetal DS, the
adjusted odds ratios of U-PDE9A level and UI were 46.2 [95% confidence interval: 7.8–151.6] and 63.7 [95% confidence
interval: 23.2–206.7], respectively.
Conclusions: Our findings suggest that U-PDE9A level and the unmethylation index of PDE9A may be useful biomarkers for
non-invasive fetal DS detection during the first trimester of pregnancy, regardless of fetal gender.
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Introduction
Prenatal testing is an integral component of obstetric practice.
Detection of chromosomal aneuploidy has been considered the
most common and important aspect of prenatal testing. Aneu-
ploidy refers to changes in the numbers of chromosomes present
inside a cell, and phenotypic effects are caused by an increased or
decreased gene dosage as a result of gaining or losing a particular
chromosome. The most common aneuploidy is trisomy 21, refered
to as Down syndrome (DS), which occurs in 1 in 800 live births
worldwide and is caused by an extra copy of all or part of
chromosome 21 [1]. DS is associated with intellectual impairment,
severe learning difficulties, and mortality caused by long-term
health problems such as heart disease [1]. The incidence of fetal
DS increases in a maternal age-dependent manner [1,2].
Worldwide, millions of pregnant women undergo prenatal
testing including screening tests and invasive diagnostic procedures
for fetal DS detection every year. The current screening protocol
for fetal DS involves a blood test for maternal protein biomarkers
associated with DS (maternal serum alpha fetoprotein, unconju-
gated estriol, human chorionic gonadotrophin, and inhibin-A) as
well as fetal ultrasound evaluations of nuchal translucency.
However, the detection rate for each factor ranges from 25% to
68% with false-positive rate of 5% [3,4]. Therefore, multiple
screening tests are usually performed to increase the detection rate
for fetal DS at 11–12 weeks and 16–18 weeks of gestation.
However, such integrated tests have disadvantages such as
increased cost due to the use of multiple biomarkers and
psychological burden on the patient as they wait to obtain results
in the second trimester (16–18 weeks of gestation). Moreover, 5%
of normal pregnant women with false-positive results undergo
unnecessary invasive diagnostic processes such as amniocentesis or
chorionic villus sampling (CVS) for fetal DS detection. Such
invasive diagnostic tests are expensive, require expert technicians,
and carry a risk of miscarriage of approximately 1% [5,6].
Therefore, non-invasive prenatal test that allow for the direct
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investigated as alternative methods to reduce the need for invasive
procedures and to improve the efficacy of current screening tests
for fetal DS.
Cyclic nucleotide phosphodiesterases (PDEs) catalyze the
hydrolysis of cyclic adenosine 30,50-monophosphate (cAMP)
and/or cyclic guanosine 30,50-monophosphate (cGMP) [7]. The
human PDE9A gene, located on chromosome 21q22.3, encodes a
cGMP-specific PDE that is expressed in most tissues, but not in
blood [8,9]. Due to its location and contribution to the regulation
of the steady-state cellular concentrations of cyclic nucleotides,
PDE9A is a possible candidate gene for diseases such as bipolar
affective disorder [9], and Guipponi et al. suggested that its
overexpression might be involved in DS [9]. Recently, Chim et al.
performed a systematic search for fetal-specific epigenetic markers
on chromosome 21 [10], during which they found that the PED9A
region is completely methylated in the maternal blood (M-PED9A)
and unmethylated in fetal (placental) tissues (U-PED9A). There-
fore, they reported that this marker was independent of fetal
gender and genotype, and hence could be applied to all fetal-
maternal pairs for non-invasive detection of fetal sequences on
chromosome 21. However, the usefulness of PED9A in the non-
invasive prenatal detection of fetal DS has not yet been clinically
validated.
The aim of this study was to estimate the accuracy of non-
invasive fetal DS detection using tissue specific-methylation in
PDE9A and to evaluate the potential of PDE9A as a new biomarker
for the first trimester detection of fetal DS.
Materials and Methods
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. Appropriate institutional review
board approval was obtained from the Ethics Committee at Cheil
General Hospital for this study (#CGH-IRB-2008-43). Written
informed consent was obtained from each participant before blood
draws for the collection of samples and subsequent analysis.
Study participants and samples
We performed a nested case-control study of women who
enrolled in the Cheil General Hospital Non-invasive Prenatal
Diagnosis Study (CNPD). Participants in the CNPD were
recruited from 2008 for non-invasive prenatal diagnosis of rare
and incurable fetal diseases. Participants were women who
received prenatal care at Cheil General Hospital. For the current
study, 108 women were selected from a larger sample of 793
women enrolled in the CNPD according to criteria described
below. All pregnancies were singletons at or before 12 weeks of
gestation between October 2008 and May 2009.
The case group consisted of 18 women who were subsequently
detected to be carrying a DS fetus by amniocentesis or CVS for
fetal karyotyping. Each case was paired with five controls that
were matched according to gestational week at blood sampling
(Table S1). The control group (n=90) included women who
delivered healthy normal neonates at term (37 weeks of gestation
or more) without medical or obstetric complications, such as
hypertension, diabetes, renal insufficiency, congenital anomalies,
or fetal demise. Before maternal blood sampling, ultrasonogra-
phy was recommended to establish the viability of each singleton
pregnancy and to confirm gestational age calculated from the
time of last menstruation. Maternal, fetal, and infant records
were collected prospectively and maintained in an electronic
database. None of the participants had histories of preexisting
hypertension, diabetes mellitus, liver disease, or chronic kidney
disease.
Isolation of Plasma and DNA
Ten milliliters of peripheral blood were collected from each
participant into ethylenediaminetetraacetic acid (EDTA) tubes.
Immediately after sampling, maternal peripheral blood samples
were centrifuged at 1,600 g for 10 minutes at 4uC and the plasma
portion was recentrifuged at 16,000 g for 10 minutes to minimize
any additional release of maternal DNA. Circulating fetal DNA
was extracted from 1.5 mL of maternal plasma using the QIAamp
DSP Virus Kit (Qiagen, Hilden, Germany), according to the
manufacturer’s recommendations. Each DNA sample was eluted
into 50 mL of sterile, DNase-free water. The samples were coded
for subsequent blinded analysis.
Quantitative methylation-specific polymerase chain
reaction (qMSP)
Differences in methylation of PDE9A in maternal blood cells
and placenta were confirmed by bisulphite genomic sequencing
(Fig. 1, Methods S1). Levels of M-PDE9A and U-PDE9A in
maternal plasma were measured by qMSP assays as previously
described [10,11].
DNA extracted from plasma was bisulphite-converted using
the EZ DNA Methylation Kit (Zymo Research, Orange, CA,
USA) and then eluted into 30 mL. For the validation of bisulphite
conversion, a synthetic DNA oligonucleotide for the U-PDE9A
region and genomic DNA extracted from peripheral blood cells
were used as positive and negative controls, respectively. The
PCR reaction solution contained 12.5 mL iQ Supermix (Bio-Rad,
Hercules, CA, USA), 200 nM hydrolysis probe (Applied Biosys-
tems, Foster City, CA, USA), 400 nM primers (Applied
Biosystems, Foster City, CA, USA), and 5 mL converted DNA
per 25 mL total reaction volume. The primers and hydrolysis
probes used for qMSP assay were as follows; for M-PDE9A,
forward primer: 59-CGG TGA GTG CGC GTC GC-39,r e v e r s e
primer: 59-CCA ACC ATC CCG AAA AAG CG-39, and probe:
59-TTC GGT GAC GTT ACG CGG T-39,f o rU-PDE9A,
forward primer: 59- GGT TTG TTT TGG TGA GTG TGT
GTC GT-39, reverse primer: 59-C C CA A CC A TC C CA A A
AAA GCA-39, and probe: 59-TTT GTT TGG TGA TGT TAT
GTG GTT T-39. The probes for M-PDE9A and U-PDE9A were
dual-labeled with 6-carboxyfluorescein (FAM) and minor groove-
binding non-fluorescent quencher (MGBNFQ). The thermal
profile consisted of an initial denaturation step of 95uCf o r1 0
minutes followed by 50 cycles of 95uC for 15 seconds, 60uCf o r
30 seconds, and 72uC for 30 seconds. Calibration curves were
prepared for each assay by serial dilutions of single-stranded
synthetic DNA oligonucleotides specific to the M-PDE9A and U-
PDE9A amplicons. The sequences of the synthetic DNA were as
follows; for M-PDE9A:5 9-CGG TGA GTG CGC GTT GCG
GGT TTT GTT CGG TGA CGT TAC GCG GTT TTT TCG
TTT TTT CGG GAT GGT TGG-39,f o rU-PDE9A:5 9-GGT
TTG TTT TGG TGA GTG TGT GTT GTG GGT TTT GTT
TGG TGA TGT TAT GTG GTT TTT TTG TTT TTT TGG
GAT GGT TGG G-39.
Levels were calculated as copies/mL as previously described
[12]. Strict precautions were taken to prevent contamination,
and multiple negative-control water blanks were included in
every analysis. To reduce inter-experimental variation, each
extraction was repeated in triplicate. The final data reflect the
means of the results (Table S2 and S3). All samples were
analyzed blindly.
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The clinical characteristics of the study population were
compared between cases and controls using the Mann-Whitney
U test and the x
2 test. The accuracy for detecting fetal DS was
analyzed with factors such as U-PDE9A level and unmethylation
index (UI). The UI is calculated as {U-PDE9A level/(M-PDE9A
level+U-PDE9A level)}X100. The accuracy of fetal DS detection
was determined with the fetal karyotyping results. Receiver
operating characteristics (ROC) curve analysis was performed to
assess the optimal cutoff value as described in our previous study
[13]. The optimal cutoff was set at a 5% false-positive rate for
comparisons with the accuracy of current screening test for fetal
DS. The sensitivity, positive predictive value (PPV), negative
predictive value (NPV), and odds ratio (OR) were calculated with
95% confidence intervals (CIs) using the EpiMax Table Calcu-
lator (http://www.healthstrategy.com/epiperl/epiperl.htm). Over-
all accuracy was estimated according to the area under the ROC
curve (AUC). Multiple logistic regression analysis was used to
estimate the values of U-PDE9A levels and UI as risk factors for fetal
DS, controlling for potential confounding factors. Potential
confounding factors included maternal age, body mass index, and
nulliparity at the time of blood sampling. Adjusted ORs (adjORs)
and their 95% CIswerecalculated. In all tests,thresholds of P,0.05
were set for statistical significance. Statistical analyses were
performed using the Statistical Package for Social Sciences 12.0
(SPSS Inc., Chicago, IL, USA).
Results
The clinical characteristics are given in Table 1. At blood
sampling, maternal age, gravidity, and body mass index did not
significantly differ between the cases and controls (P.0.05 for all).
The median gestational age was 7.5 weeks in both case and control
groups. Forty-four percent of participants in the case group and
41% of participants in the control group were nulliparous; this
difference between cases and controls was not significant
(P=0.799). Fetal gender-ratio and tobacco use also were not
different between the two groups (P.0.05 for both).
In the analysis of M-PDE9A and U-PDE9A levels according to
fetal gender, median levels of M-PDE9A were 1956.0 (interquartile
range: 1592.5–2411.2) and 2023.1 (interquartile range: 1650.0–
2310.3) copies/mL in male and female fetus-bearing participants,
Figure 1. Bisulfite genomic sequencing of PDE9A. The red characters in the sequences indicate methylation CpG sites of the PDE9A gene.
Methylated CpG sites of PDE9A were detected in maternal blood cells and placental tissues. Unmethylated CpG sites of PDE9A were detected only in
placental tissues. Yellow boxes indicate the regions that were amplified by the methylation-specific polymerase chain reaction.
doi:10.1371/journal.pone.0027709.g001
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155.1–308.4) and 209.6 (interquartile range: 156.3–283.5) copies/
mL in male and female fetus-bearing participants, respectively.
Levels of M-PDE9A and U-PDE9A were not significantly different
between fetal genders (P.0.05 for all, Fig. 2). In the analysis of M-
PDE9A and U-PDE9A levels according to fetal karyotype, levels of
M-PDE9A were not different between the DS cases and controls
[1854.3 (interquartile range: 1653.3–2446.3) vs 2004.5 (interquar-
tile range: 1605.2–2316.9)copies/mL, P=0.928, Fig. 3]. However,
levels of U-PDE9A were significantly higher in the cases compared
to controls [356.8 (interquartile range: 314.8–437.4) vs 194.7
(interquartile range: 143.0–263.6) copies/mL, P,0.001, Fig. 3].
The accuracies of U-PDE9A level and UI for the detection of
fetal DS are shown in Table 2. The cutoff value for each factor was
set at the 5% false-positive rate by ROC analysis. Sensitivity, PPV,
and NPV were compared at an equivalent false-positive rate. The
ROC curves of U-PDE9A level and UI are presented in Fig. 4. The
U-PDE9A cutoff level of 320 copies/mL had a sensitivity of 77.8%,
PPV of 73.7%, and NPV of 95.5% in differentiating women
carrying a DS fetus from women carrying a normal fetus, and the
AUC was 0.907 (95% CI: 0.833–0.981) with a standard error (SE)
of 0.038 (P,0.001). The UI cutoff value of 14 had a sensitivity of
83.3%, PPV of 75.0%, NPV of 96.6%, and the AUC was 0.927
(95% CI: 0.851–1.003) with an SE of 0.039 (P,0.001). These
findings were confirmed using sample karyotypes (Table S1).
We analyzed the accuracy of U-PDE9A levels and UI for
detecting fetal DS based on gestational weeks at blood sampling
(Table 3). The sensitivity of U-PDE9A level was higher at 9–12
weeks of gestation than at 5–8 weeks of gestation, whereas the
sensitivity of UI was higher at 5–8 weeks of gestation than at 9–12
weeks of gestation. The specificities of both tests were higher at 9–
12 weeks of gestation than at 5–8 weeks of gestation. All cases
showing false-positive and false-negative results were observed at
or before a gestational age of 10 weeks (Table 4).
We analyzed the associations between each factor and the risk
of DS. As listed in Table 5, the risk of DS was significantly
increased in women with values greater than the cutoff values
compared with women whose values were less than the cutoff
values for U-PDE9A level or UI (OR [95% CI]: 59.5 [12.1–340.7]
for U-PDE9A level, 85.0 [15.5–564.2] for UI). After adjusting for
potential confounding factors such as maternal age, body mass
index, and nulliparity at blood sampling, the adjORs of U-PDE9A
level and UI were 46.2 (95% CI: 7.8–151.6) and 63.7 (95% CI:
23.2–206.7), respectively. Women with U-PDE9A levels and UI
greater than the cutoff values were at dramatically higher risk of
fetal DS in both unadjusted and adjusted analyses, compared with
women with values less than the cutoff values.
Discussion
Our findings demonstrate that U-PDE9A and UI are effective
biomarkers for the non-invasive detection of fetal DS during the
Table 1. Clinical characteristics in cases and controls.
Characteristics Case (N=18) Control (N=90) P value
At blood sampling
Maternal age (years) 36.1 (31.3–38.0) 31.1 (29.1–34.8) 0.059
a
Gestational age (weeks) 7.5 (6.0–9.0) 7.5 (6.0–9.0) 0.999
a
Body mass index (kg/m
2) 22.2 (20.6–24.0) 21.4 (19.3–23.3) 0.180
a
Nulliparity 8 (44.4) 37 (41.1) 0.799
b
Gravidity 2.0 (1.0–3.3) 2.0 (2.0–3.0) 0.331
a
Gender-ratio of fetus
(male:female)
7:11 44:46 0.606
b
Tobacco use 1 (5.6) 6 (6.7) 0.999
b
Values are median (interquartile range) or number (%).
a: Mann-Whitney U test, b: x
2 test.
doi:10.1371/journal.pone.0027709.t001
Figure 2. Levels of M-PDE9A and U-PDE9A in maternal plasma according to fetal gender. The upper and lower limits of the boxes and the
lines across the boxes indicate the 75
th/25
th percentiles and the medians, respectively. The upper and lower error bars indicate the 90
th and 10
th
percentiles, respectively. The circles indicate outliers. Levels were analyzed by the Mann-Whitney U-test.
doi:10.1371/journal.pone.0027709.g002
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and UI were significantly elevated in pregnant women carrying
DS fetuses compared to women carrying normal fetuses in the first
trimester, regardless of fetal gender. Moreover, pregnant women
with high values for U-PDE9A and UI were at an increased risk of
carrying a DS fetus. Therefore, we suggest that U-PDE9A and UI
may be useful biomarkers for non-invasive fetal DS detection using
circulating fetal DNA from maternal plasma, regardless of fetal
gender.
Current screening tests for fetal DS detection increases detection
rate by integration of multiple methods, such as measurement of
nuchal translucency and blood tests for numerous maternal serum
markers, including alpha fetoprotein, unconjugated estriol, human
chorionic gonadotrophin, and inhibin-A, but at a higher screen-
positive rate (approximately 16–22%) [3,4]. Moreover, diagnostic
test currently requires obtaining samples of fetal cells directly from
the uterus for genetic analysis, either through CVS between 11
and 14 weeks gestation or amniocentesis after 15 weeks. However,
these invasive procedures present a small but significant risk of
miscarriage in normal pregnancies [5,6]. Therefore, the develop-
ment of non-invasive prenatal tests for DS detection using
circulating fetal DNA in maternal plasma has been considered
as a potential alternative to improve current screening tests and to
reduce the need for invasive procedures, such as amniocentesis or
CVS.
Epigenetics is the study of molecular phenomena that affect
gene expression, but which do not involve alterations in DNA
sequences. The best-studied epigenetic phenomenon is the process
of DNA methylation, which suppresses gene expression and
Figure 3. Levels of M-PDE9A and U-PDE9A in maternal plasma according to fetal karyotype. The upper and lower limits of the boxes and
the lines across the boxes indicate the 75
th/25
th percentiles and the medians, respectively. The upper and lower error bars indicate the 90
th and 10
th
percentiles, respectively. Levels were analyzed by the Mann-Whitney U-test.
doi:10.1371/journal.pone.0027709.g003
Figure 4. The ROC curves of U-PDE9A level and unmethylation
index. The ROC curves of unmethylation index and U-PDE9A level are
represented by blue and red lines, respectively.
doi:10.1371/journal.pone.0027709.g004
Table 2. The utility of measurements for detection of fetal
Down syndrome.
Cutoff Sensitivity PPV NPV
U-PDE9A level (copies/
mL)
320 0.778
(0.557–0.891)
0.737
(0.537–0.863)
0.955
(0.912–0.982)
Unmethylation index 14 0.833
(0.635–0.940)
0.750
(0.563–0.855)
0.966
(0.923–0.990)
The cutoff was set at 5% false positive rate by ROC curve analysis. To compare
detection accuracies of factors, sensitivity, positive predictive value (PPV), and
negative predictive value (NPV) were calculated at equivalent false positive rate.
The number in parentheses indicates the 95% confidence interval.
doi:10.1371/journal.pone.0027709.t002
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demonstrated that it was possible to develop fetal DNA markers
based on differential DNA methylation patterns between maternal
and fetal tissues [15]. This strategy has led to the recognition that
the SERPINB5 gene on chromosome 18, which codes for maspin,
is hypomethylated in the placenta, but hypermethylated in
maternal blood cells [15]. Therefore, it has been suggested that
the measurement of the ratio of single nucleotide polymorphisms
(SNP) in the hypomethylated version of the SERPINB5 gene might
allow the detection of fetal trisomy 18 [16].
Similar studies have been performed for non-invasive prenatal
detection of fetal DS using circulating fetal DNA. Recently,
Papageorgiou et al. reported that the application of fetal-specific
methylation ratio led to correct diagnosis of fetal DS [17] and
Tong et al. reported that epigenetic-genetic chromosome dosage
using hypermethylated HLCS and a paternally inherited fetal SNP
allele could be applied for the prenatal diagnosis of trisomy 21 for
both male and female fetuses [18]. However, these studies were
performed with maternal blood samples that were taken during
the late-first or second trimesters (11.1–14.4 weeks of gestation in
Papageorgiou et al. [17]; 12–21 weeks of gestation in Tong et al.
[18]) and the samples ware small (14 cases and 26 controls in a
blinded analysis by Papageorgiou et al. [17]; 14 cases and 33
controls in Tong et al. [18]). Moreover, these studies did not
control for gestational weeks at blood sampling, which can affect
the concentrations of circulating fetal DNA [17,18]. Despite these
limitations, previous studies suggest that diagnostic strategies using
fetal-specific epigenetic markers may be advantageous compared
to current biochemical screening methods for fetal DS. Therefore,
searches for fetal-specific epigenetic markers on chromosome 21
Table 3. Detection accuracy according to gestational weeks.
Gestational
weeks
Case
(correct N/total N)
Control
(correct N/total N) Sensitivity Specificity PPV NPV
U-PDE9A
Level
5–8 10/13 61/65 0.769
(0.509–0.925)
0.938
(0.886–0.970)
0.714
(0.472–0.859)
0.953
(0.900–0.985)
9–12 4/5 24/25 0.800
(0.347–0.982)
0.960
(0.869–0.996)
0.800
(0.347–0.982)
0.960
(0.869–0.996)
Unmethylation index 5–8 11/13 61/65 0.846
(0.588–0.970)
0.938
(0.887–0.963)
0.733
(0.510–0.841)
0.968
(0.915–0.994)
9–12 4/5 24/25 0.800
(0.347–0.982)
0.960
(0.869–0.996)
0.800
(0.347–0.982)
0.960
(0.869–0.996)
PPV, positive predictive value; NPV, negative predictive value.
The number in parentheses indicates the 95% confidence interval.
doi:10.1371/journal.pone.0027709.t003
Table 4. Cases showing false-positive and false-negative results.
Factors Condition Value Gestational weeks Karyotype
U-PDE9A level
(cutoff: 320 copies/mL)
False-negative
(N=4)
228.4 6 47,XX,+21
280.6 6 47,XX,+21
186.6 7 47,XY,+21
255.9 9 47,XX,+21
False-positive
(N=5)
361.6 6 46,XX
381.1 7 46,XY
345.9 7 46,XX
351.8 8 46,XX
366.5 10 46,XY
Unmethylation index (cutoff: 14) False-negative
(N=3)
9.5 6 47,XX,+21
8.7 7 47,XY,+21
12.9 9 47,XX,+21
False-positive
(N=5)
16.5 6 46,XY
15.8 7 46,XX
14.9 8 46,XY
14.4 8 46,XX
15.3 10 46,XY
doi:10.1371/journal.pone.0027709.t004
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Recently, Chim et al. performed a systematic search for such
markers on chromosome 21 [10] and reported that 22 of the 114
studied genomic regions were differentially methylated between
maternal and fetal (placental) tissues. On the basis of this tissue-
specific methylation, they proposed the use of fetal-DNA markers,
such as U-PDE9A, which are completely methylated in maternal
blood cells but unmethylated in the placenta for non-invasive
prenatal detection of fetal sequences on chromosome 21.
However, the usefulness of such markers in non-invasive prenatal
test for fetal DS has not yet been confirmed.
In the present study, we investigated the utility and accuracy of
U-PDE9A levels and UI for use in non-invasive prenatal detection
of DS using circulating fetal DNA from the first trimester. We
conducted a nested case-control study controlling for gestational
weeks at blood sampling; each case was matched carefully with 5
controls according to gestational weeks at blood sampling (Table
S1). Furthermore, all samples were obtained during the first
trimester (12 weeks of gestation or less) and the sample number
was larger than those of prior studies [17,18]. In this study, U-
PDE9A levels and UI were significantly elevated during the first
trimester in pregnant women carrying DS fetuses, regardless of
fetal gender. The fetal DS detection rates of the two factors were
higher than those of serum screening markers and nuchal
translucency measurements, which are generally performed in the
first trimester [3,4]. Moreover, the detection rates of U-PDE9A
and UI for fetal DS were far superior to those of Y chromosome-
specific markers, such as DYS14 or SRY, in maternal serum [19].
Furthermore, Y chromosome-specific markers are limited to use
for male fetuses. Therefore, we suggest that U-PDE9A levels and
UI are effective markers for use in non-invasive prenatal
detection of DS during the first trimester regardless of fetal
gender, and in fact, these markers may detect fetal DS more
effectively than current screening tests for fetal DS. However, the
sensitivities of U-PDE9A level and the UI were lower or similar
(77.8% for U-PDE9A levels and 83.3% for UI) than those of
second trimester quadruple screening tests (81%). Moreover,
false-positive and false-negative results were observed at or before
10 weeks of gestational age. Accordingly, non-invasive fetal DS
detection using these markers may have limited clinical
applications prior to 10 weeks of gestation. Therefore, improve-
ments in detection rate by applications of other detection
methods such as digital PCR or direct comparisons with fetal-
specific DNA markers on reference chromosomes may facilitate
the clinical use of these markers.
In non-invasive prenatal testing, the analysis of fetal genetic loci
in maternal plasma is still problematic because circulating fetal
DNA is present in small amounts. To solve this problem, many
researchers have suggested methods such as size fractionation
[20,21]. Prior studies have demonstrated that more than 99% of
circulating fetal DNA is less than 313 bp in length, whereas
circulating maternal DNA is significantly longer [20,21]. This
discovery enables the possibility of circulating fetal DNA
enrichment by size fractionation using a number of methods.
Most simply, gel electrophoresis of DNA extracted from maternal
plasma has been used to select for low molecular weight DNA.
Other methods include the use of kits and columns that rely either
on the inability of large molecular weight DNA to pass through, or
by the retention of low molecular weight DNA [22,23]. In recent
studies, Clausen et al. reported that using the DSP Virus Kit
resulted in a higher yield of circulating fetal DNA compared with
total circulating DNA from maternal plasma [22]. Legler et al.
suggested that the DSP Virus Kit is an optimal method for
extracting high yields of circulating fetal DNA from total plasma
[23]. In this study, we used the DSP Virus Kit to extract
circulating fetal DNA from maternal plasma. Therefore, we were
able to detect fetal DNA identifiers, such as U-PDE9A, at as early
as five weeks of gestation.
To our knowledge, this is the first study to estimate the accuracy
of non-invasive fetal DS detection using U-PDE9A analysis in
circulating fetal DNA from first trimester maternal plasma. Our
data indicate that U-PDE9A and UI may be useful markers for
non-invasive prenatal detection for fetal DS in all fetal-maternal
pairs, regardless of fetal gender. Additionally, high U-PDE9A levels
and UI may be suitable biomarkers for identifying pregnant
women carrying fetuses with DS. Accordingly, these markers may
be useful in the development of effective and reliable tests for non-
invasive detection of fetal DS. However, the use of this method
may create ethical and social issues because the results may impact
decisions to terminate or continue the pregnancy. Therefore, the
use of this method should be carefully considered in clinical
situation and should not be used in the present clinical settings
unless more research is done. Furthermore, this method needs to
be further refined to achieve higher sensitivity and specificity.
Additionally, this study is limited by its small sample size and
inclusion of only Korean patients. Therefore, a larger-scale study
within different ethnic populations will need to be performed to
assist the introduction of the diagnostic strategy used in this study.
Supporting Information
Methods S1 There are included sample processing and
DNA extraction for bisulfite genomic sequencing of
PDE9A, bisulfite genomic sequencing of PDE9A, and
Table 5. Odds ratios for fetal Down syndrome.
Case
(N=18)
Control
(N=90) Unadjusted OR (95%CI)
Adjusted OR
(95% CI)*
U-PDE9A level (copies/mL)
Lower than 320 4 85 1.0 1.0
320 or higher 14 5 59.5 (12.1–340.7) 46.2 (7.8–151.6)
Unmethylation index
Lower than 14 3 85 1.0 1.0
14 or higher 15 5 85.0 (15.5–564.2) 63.7 (23.2–206.7)
OR, odds ratio; CI, confidence interval.
*Adjusted for maternal age, body mass index, and nullipara at blood sampling.
doi:10.1371/journal.pone.0027709.t005
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